Aliases & Classifications for Lens Disease

Summaries for Lens Disease

MalaCards based summary : Lens Disease, also known as lens diseases, is related to cataract and isolated ectopia lentis, and has symptoms including eye manifestations An important gene associated with Lens Disease is CRYAA (Crystallin Alpha A). The drugs Estradiol and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and testes, and related phenotypes are no effect and growth/size/body region

Wikipedia : 77 The lens is a transparent, biconvex structure in the eye that, along with the cornea, helps to refract... more...

Related Diseases for Lens Disease

Graphical network of the top 20 diseases related to Lens Disease:



Diseases related to Lens Disease

Symptoms & Phenotypes for Lens Disease

UMLS symptoms related to Lens Disease:


eye manifestations

GenomeRNAi Phenotypes related to Lens Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ABHD12 ADAMTSL4 AKR1B1 CLOCK CRYAA CRYBB2

MGI Mouse Phenotypes related to Lens Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10 AKR1B1 CLOCK ERCC6 FBN1 LAMA3 MYH9
2 homeostasis/metabolism MP:0005376 9.93 ABHD12 AKR1B1 CLOCK ERCC6 FBN1 LAMA3
3 renal/urinary system MP:0005367 9.5 AKR1B1 FBN1 MYH9 OCRL PAX6 PHEX
4 vision/eye MP:0005391 9.4 ABHD12 ADAMTSL4 AKR1B1 CRYBB2 CRYGS ERCC6

Drugs & Therapeutics for Lens Disease

Drugs for Lens Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
2
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-63-6 5991
3
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
4
Besifloxacin Approved Phase 4,Phase 1 141388-76-3
5
Moxifloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
6
Norgestimate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 35189-28-7 6540478
7
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
8
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 1 82034-46-6, 129260-79-3 9865442 444025
9
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
11
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
13
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 74103-06-3, 66635-83-4 3826
14
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
15
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 9004-61-9 53477741
16
Gabapentin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 60142-96-3 3446
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
19
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 5311068 68602
20
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 46507594 772
21
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 32986-56-4 36294 5496
22
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
23
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
24
Ephedrine Approved Phase 4,Phase 3,Not Applicable 299-42-3 9294
25
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
26
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
27
Phenylephrine Approved Phase 4,Phase 3,Not Applicable 59-42-7 6041
28
Oxymetazoline Approved, Investigational Phase 4,Phase 3,Not Applicable 1491-59-4 4636
29
Pseudoephedrine Approved Phase 4,Phase 3,Not Applicable 90-82-4 7028
30
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 2078-54-8 4943
31
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
32
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
33
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
34
Dinoprostone Approved Phase 4,Not Applicable 363-24-6 5280360
35
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Not Applicable 82419-36-1 4583
36
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 100986-85-4 149096
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
38
tannic acid Approved Phase 4,Not Applicable 1401-55-4
39
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
40 Orange Approved Phase 4
41
Azithromycin Approved Phase 4 83905-01-5 447043 55185
42
Gatifloxacin Approved, Investigational Phase 4,Phase 1,Not Applicable 112811-59-3 5379
43
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2 85721-33-1 2764
44
Bimatoprost Approved, Investigational Phase 4,Phase 2 155206-00-1 5311027
45
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
46
Dalteparin Approved Phase 4 9005-49-6
47
Enoxaparin Approved Phase 4 9005-49-6 772
48
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
49
Difluprednate Approved Phase 4,Phase 3 23674-86-4 443936
50
Fluprednisolone Approved Phase 4,Phase 3 53-34-9

Interventional clinical trials:

(show top 50) (show all 882)
# Name Status NCT ID Phase Drugs
1 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
2 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
3 Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens Unknown status NCT01615861 Phase 4
4 Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Unknown status NCT01382641 Phase 4
5 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
6 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
7 Efficacy of Subtenon's Block With Olive Tipped Cannula Unknown status NCT01019018 Phase 4
8 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
9 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
10 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
11 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
12 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
13 Spherical Aberration and Contrast Sensitivity in IOLs Completed NCT00576485 Phase 4
14 Sedation Methods During Cataract Surgery Completed NCT03054103 Phase 4 Midazolam + Ketamine 10 MG/ML: 0.5 ML;Midazolam + Ketamine 10 MG/ML: 1 ML;Midazolam + Normal saline
15 Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size Completed NCT02895035 Phase 4 Phenylephrine-ketorolac;Epinephrine
16 Patient-controlled Sedation With Propofol During Cataract Surgery Under Topical Anesthesia Completed NCT02771912 Phase 4 Propofol;Placebo
17 Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL Completed NCT02770924 Phase 4
18 Visual Acuity After the Combined Binocular Implantation of +2.0 Diopters and +3.0 Diopters Oculentis Multifocal Intraocular Lenses. Completed NCT02633228 Phase 4
19 Visual Acuity After the Combined Binocular Implantation of +2.75 Diopters and +3.25 Diopters Tecnis Multifocal Intraocular Lenses. Completed NCT02633072 Phase 4
20 Dropless vs. Standard Drops Contralateral Eye Study Completed NCT02515045 Phase 4 TriMoxiVanc;Moxifloxacin HCl 0.5%;Ilevro;Prednisolone acetate 1%
21 Visual Acuity After the Combined Binocular Implantation of +2.5 Diopters and +3.0 Diopters ReSTOR Multifocal Intraocular Lenses. Completed NCT02314572 Phase 4
22 A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria Completed NCT02150460 Phase 4
23 Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification Completed NCT02089698 Phase 4
24 Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery Completed NCT02023437 Phase 4
25 Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure Completed NCT01971177 Phase 4
26 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
27 A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery Completed NCT01769313 Phase 4
28 Time Study for Biometry Measurements With the Lenstar and IntraOcularLens (IOL) Master 500 Completed NCT01550939 Phase 4
29 Visual Outcomes After Implantation of a New Multifocal Intraocular Lens Completed NCT01505816 Phase 4
30 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Completed NCT01455233 Phase 4 besivance;vigamox
31 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
32 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
33 Comparison of Postoperative Visual Acuity and Spectacle Independence Between the Tecnis Multifocal Intraoculer Lens (IOL) and the Crystalens Accommodating IOL Completed NCT01275118 Phase 4
34 Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL Completed NCT01248572 Phase 4
35 Clinical Evaluation of the One-Piece Tecnis Multifocal Intraocular Lens (IOL) Completed NCT01210807 Phase 4
36 Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery Completed NCT01199510 Phase 4
37 Evaluation of 3 Intraocular Lenses Following Lens Extraction Completed NCT01122576 Phase 4
38 Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses Completed NCT01061918 Phase 4
39 Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses Completed NCT01061281 Phase 4
40 Spherical Aberration and Contrast Sensitivity Function in Eyes Implanted With Spherical and Aspheric Intraocular Lenses: A Clinical Trial Completed NCT01028872 Phase 4
41 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
42 Outcomes of Phacoemulsification With Torsional Ultrasound Completed NCT01010490 Phase 4
43 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
44 Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront Completed NCT00999492 Phase 4
45 Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL Completed NCT00934622 Phase 4
46 Check of Optical Features and Accuracy of the Zeiss ZO Lens After Selection and Calculation With OKULIX Completed NCT00842959 Phase 4
47 Effect on Wound Healing of Vigamox Versus Cravit Completed NCT00840580 Phase 4 Moxifloxacin 0.5% ophthalmic solution (Vigamox);Levofloxacin 0.5% ophthalmic solution (Cravit)
48 Evaluation of the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL Intraocular Lens Completed NCT00838045 Phase 4
49 Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL Completed NCT00818116 Phase 4
50 Clinical Evaluation of a New Aspheric Intraocular Lens. Completed NCT00786565 Phase 4

Search NIH Clinical Center for Lens Disease

Cochrane evidence based reviews: lens diseases

Genetic Tests for Lens Disease

Anatomical Context for Lens Disease

MalaCards organs/tissues related to Lens Disease:

42
Eye, Endothelial, Testes, Retina, Bone, Prostate

Publications for Lens Disease

Articles related to Lens Disease:

# Title Authors Year
1
Diagnosis and treatment of lens diseases. ( 1458330 )
1992
2
Documentation of lens diseases. ( 511290 )
1979
3
Concomitant progressive deafness, chronic nephritis, and ocular lens disease. ( 13950238 )
1963

Variations for Lens Disease

Expression for Lens Disease

Search GEO for disease gene expression data for Lens Disease.

Pathways for Lens Disease

GO Terms for Lens Disease

Cellular components related to Lens Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 connexin complex GO:0005922 8.62 GJA3 GJA8

Biological processes related to Lens Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.46 CRYAA CRYBB2 GJA3 PAX6
2 positive regulation of neuroblast proliferation GO:0002052 9.43 PAX6 VEGFA
3 eye photoreceptor cell development GO:0042462 9.4 PAX6 VEGFA
4 monocyte differentiation GO:0030224 9.37 MYH9 VEGFA
5 cornea development in camera-type eye GO:0061303 9.32 FOXE3 PAX6
6 iris morphogenesis GO:0061072 9.26 FOXE3 PAX6
7 lens development in camera-type eye GO:0002088 9.26 CRYGS FOXE3 GJA8 PAX6
8 camera-type eye development GO:0043010 9.02 CRYBB2 FBN1 FOXE3 GJA8 PAX6

Molecular functions related to Lens Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 8.8 CRYAA CRYBB2 CRYGS
2 gap junction channel activity GO:0005243 8.65 GJA8

Sources for Lens Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....